Report on a direct-to-brain regenerative stem cell therapy for Alzheimer’s progressing toward accelerated clinical development and broader trials.
Key Takeaways
- Therapy received Fast Track designation from the U.S
- It uses Wnt-activated autologous adipose-derived stem cells delivered directly into the brain
- First-in-human trial reported safety and biomarker improvements, prompting a randomized Phase II trial